Group 1 - Company repurchased 100,000 shares at a cost of HKD 924,000 on November 5 [1] - The repurchase is part of the company's strategy to manage its capital and enhance shareholder value [1] - The company is preparing for the complete analysis of the ASC30 oral tablet Phase Ib study at the 2025 ObesityWeek® [1] Group 2 - The company is also conducting Phase Ib studies for ASC30 injection and preclinical studies for ASC31 and ASC47 combination therapy [1]

Core Insights - Company announced multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, showcasing the efficacy and safety of its obesity treatment pipeline, including ASC30, ASC31, and ASC47 [1] Group 1: Clinical Research - The complete analysis of the ASC30 oral tablet in Phase Ib trials was presented [1] - A Phase Ib study of ASC30 as a monthly injection was also reported [1] - Preclinical studies on the combination of ASC31 and ASC47 were highlighted [1] Group 2: Technology and Development - The reports emphasize the promising efficacy and safety characteristics of the company's small molecules and peptides for obesity treatment [1] - The proprietary AI-assisted drug discovery platform (AISBDD) and ultra-long-acting drug development platform (ULAP) were validated through these studies [1] Group 3: Strategic Focus - The company is committed to advancing the clinical development of ASC30, ASC31, and ASC47 while engaging closely with strategic partners [1] - The goal is to better meet the treatment needs of obesity patients globally [1]

Core Insights - The announcement highlights multiple reports presented at the 2025 ObesityWeek in Atlanta, Georgia, focusing on the efficacy and safety of the company's obesity treatment pipeline [1] - The reports include a complete analysis of the ASC30 oral tablet Phase Ib study, the ASC30 monthly injection Phase Ib study, and preclinical studies of ASC31 and ASC47 combination therapy [1] - The company's proprietary technologies, including AI-assisted drug discovery and ultra-long-acting drug development platforms, are emphasized as key components of their research [1] - The CEO expresses a commitment to advancing clinical development while engaging closely with strategic partners to meet global obesity treatment needs [1]

Core Viewpoint - The announcement highlights the promising efficacy and safety characteristics of the diverse obesity pipeline of the company, showcasing its proprietary AI-assisted drug discovery and ultra-long-acting drug development platforms [1] Group 1: Clinical Research Updates - The company presented multiple reports at the 2025 ObesityWeek in Atlanta, Georgia, including a complete analysis of the ASC30 oral tablet Phase Ib study and the ASC30 monthly injection Phase Ib study [1] - Additionally, the company reported on preclinical studies involving ASC31 and ASC47 combination therapy [1] Group 2: Strategic Focus - The CEO emphasized the ongoing clinical development of ASC30, ASC31, and ASC47 while maintaining close consultations with strategic partners to better meet the treatment needs of global obesity patients [1]

Core Viewpoint - The company, Gilead Sciences-B (01672.HK), announced multiple reports to be presented at the 2025 ObesityWeek in Atlanta, Georgia, highlighting the efficacy and safety of its obesity treatment pipeline, including ASC30, ASC31, and ASC47 [1] Group 1 - The reports will include a complete analysis of the Phase Ib study of ASC30, a monthly injection study of ASC30, and preclinical studies of ASC31 and ASC47 combination therapy [1] - The presentations demonstrate the promising efficacy and safety characteristics of Gilead's small molecules and peptides in the obesity treatment pipeline [1] - The CEO, Dr. Wu Jinzi, emphasized the importance of strategic partnerships to better meet the treatment needs of global obesity patients while advancing the clinical development of ASC30, ASC31, and ASC47 [1]

Core Insights - Ascletis Pharma Inc. presented promising data from Phase Ib studies of its obesity treatment candidates, ASC30 and the combination of ASC31 and ASC47, at ObesityWeek 2025, highlighting their efficacy and safety profiles [4][15]. Group 1: ASC30 Oral Tablet - The Phase Ib study of ASC30 oral tablet demonstrated a placebo-adjusted mean body weight reduction of up to 6.5% after 28 days of treatment, with the highest dose (60 mg) showing a maximum reduction of 9.3% [1][8]. - The study reported mild-to-moderate gastrointestinal adverse events (AEs), with no serious adverse events (SAEs) observed across all cohorts [7][8]. - The safety profile of ASC30 was consistent with or better than that of the GLP-1R agonist class, indicating it is safe and well tolerated [8]. Group 2: ASC30 Subcutaneous Injection - The Phase Ib study of ASC30 subcutaneous injection revealed an observed half-life of 46 days for the treatment formulation and 75 days for the maintenance formulation, supporting once-monthly and once-quarterly dosing [2][10]. - Similar to the oral tablet, the subcutaneous formulations were well tolerated, with only mild-to-moderate treatment-emergent adverse events reported [11][9]. - No serious adverse events or significant safety signals were detected, reinforcing the safety of ASC30 formulations [9][10]. Group 3: Combination of ASC31 and ASC47 - The combination of ASC31 and ASC47 significantly outperformed both tirzepatide and ASC31 monotherapy in weight loss, achieving a 44.8% reduction in weight compared to 19.1% for ASC31 alone, representing a 134% greater reduction [12][13]. - The combination also demonstrated superior results in body fat loss and muscle preservation, restoring the body composition of obese mice to that of healthy non-obese mice [13]. - ASC31 is a dual GLP-1R and GIPR peptide agonist, while ASC47 is designed for targeted delivery to adipose tissue, showcasing Ascletis' innovative approach in obesity treatment [12][13].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈在美國佐治亞州亞特蘭大舉行的2025年 肥胖周（ObesityWeek®）以壁報形式進行多項報告，包括ASC30每日一次口服片Ib 期研究的完整分析、ASC30每月一次注射劑Ib期研究以及ASC31與ASC47聯合用 藥臨床前研究。 1 自願性公告 歌禮在2025年肥胖周（ObesityWeek®）報告ASC30口服片 Ib期研究的完整分析、ASC30注射劑Ib期研究 以及ASC31與ASC47聯合用藥臨床前研究 － ASC30口服片Ib期研究的積極數據顯示，安慰劑校準後的平均體重下降高達 6.5%；在所 ...

Core Insights - Ascletis Pharma Inc. is presenting multiple posters on its obesity treatment programs, including ASC30, at ObesityWeek 2025 in Atlanta, Georgia, highlighting advancements in its obesity portfolio [1][2]. Group 1: Product Details - ASC30 is an investigational GLP-1 receptor biased small molecule agonist, designed for both oral and subcutaneous administration, with patent protection until 2044 [3]. - ASC31 is a novel peptide agonist targeting GLP-1R and GIPR, showing favorable pharmacokinetics and efficacy in diet-induced obese mice [4]. - ASC47 is a once-monthly subcutaneous injected small molecule agonist targeting thyroid hormone receptor beta, designed for adipose tissue targeting [5]. Group 2: Event Information - ObesityWeek 2025 will take place from November 4 to 7, 2025, featuring the latest developments in obesity research and treatment [7]. - Presentations at the event include a full analysis of a 28-day study of ASC30 and comparisons of ASC31 and ASC47 against existing treatments [2]. Group 3: Company Overview - Ascletis Pharma Inc. focuses on developing best-in-class therapeutics for metabolic diseases, utilizing proprietary technologies for drug discovery [8].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 Ascletis Pharma Inc. 歌禮製藥有限公司 歌禮將攜ASC30口服片、ASC30注射劑和ASC31與ASC47聯合療法的 研究結果亮相2025年肥胖周（ObesityWeek®） 本公告乃歌禮製藥有限公司（「本公司」或「歌禮」，連同其附屬公司稱為「本集 團」）自願作出，以使本公司股東及潛在投資者了解本集團的最新業務發展。 本公司董事（「董事」）會（「董事會」）宣佈將在美國佐治亞州亞特蘭大舉行的2025 年肥胖周（ObesityWeek®）以壁報形式報告多款肥胖症候選藥物，包括ASC30以及 ASC31與ASC47聯合療法。 報告細節： ASC30是一款正在臨床研究中的小分子GLP-1R偏向激動劑，具有獨特和差異化性 質，使得同一小分子同時適用於口服片劑和皮下注射給藥成為可能。ASC30是一 種新化學實體(NCE)，擁有 ...

Market Overview - The Hang Seng Index is expected to challenge the 26,000 point mark due to stable economic performance in mainland China and a lack of willingness to implement further economic stimulus measures [1] - The agreement between China and the US to extend the tariff truce and the active trading in Hong Kong stocks contribute to a positive risk appetite [1] - The upcoming earnings reports from major technology stocks could provide momentum for the market [1] Macro Focus - In July, industrial production, consumption, and fixed asset investment in mainland China all showed signs of slowing down, with fixed asset investment reaching a five-year low [2][7] - The People's Bank of China is implementing a moderately loose monetary policy to support economic growth [7] - Hong Kong's GDP growth for Q2 was 3.1%, maintaining the annual growth forecast at 2% to 3% [7] Company News - China Hongqiao's mid-term profit increased by 35% to 12.4 billion RMB, exceeding expectations [2] - Standard Chartered's stock price fell due to allegations from US lawmakers [3] - Huahong Semiconductor plans to acquire Huahong Microelectronics, with A-shares suspended from trading [3] Sector Highlights - The mobile device sector is anticipating the launch of Apple's iPhone 17 on September 9 [6] - The biopharmaceutical sector is benefiting from adjustments in commercial insurance for innovative drugs [6] - The humanoid robotics sector is seeing accelerated adoption due to new product launches at the World Robot Conference [6] International Market Insights - The US Federal Reserve maintained interest rates, indicating a cautious approach towards future rate cuts due to high inflation uncertainty [3] - The US retail sales in July increased by 0.5%, marking the tenth consecutive month of growth [8] - The consumer confidence index in the US unexpectedly declined in August, reflecting concerns over tariffs [8] Investment Trends - Significant inflow of capital from mainland investors into Hong Kong stocks, with net purchases reaching a historical high of 35.9 billion HKD [7] - The overall investment sentiment remains positive, driven by low valuations in Hong Kong stocks and the rise of technology companies [7]